Concepedia

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%

Liran Holtzman, Mor Moskovitz, Damien Urban, Hovav Nechushtan, S. Keren, Daniel Reinhorn, Mira Wollner, Sameh Daher, Yakir Rottenberg, Yulia Rovitzky,

Clinical Lung Cancer · 2021 · 24 citations · 39 references

DOI

Concepts

References

39

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text

, , +16

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

, , +17

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

, , +15

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Yasumasa Ishida, Yasutoshi Agata, Kei‐ichi Shibahara et al. · The EMBO Journal · 1992 · 3.2K citations · Full text

, , +12